Opened in 2012, the Jacobs Institute is a nonprofit Buffalo medical innovation center created to advance vascular care by bringing clinical expertise into the development of medical technology. Its unusual setting between a university research institute and a vascular hospital lets device innovators work alongside practicing physicians, with the Idea to Reality Center supporting projects from early concepts through clinical preparation. The Institute also trains medical professionals and industry participants in a hands-on environment.
ISO 13485:2016
Rookery LabsRookery Labs operates a Western New York innovation incubator for medical-device research, development, and engineering. Based in Buffalo, the company brings researchers, engineers, and healthcare professionals together while developing medical-technology talent and supporting healthcare ventures. Its quality system is certified to ISO 13485.BUFFALO, NY
Image Monitoring USAImage Monitoring USA is the Buffalo-based American arm of Image Monitoring Canada, drawing on its parent company’s 30 years of success in vascular diagnostics. It equips medical facilities with non-invasive vascular testing technology and stays involved through installation, staff education, and ongoing technical service.BUFFALO, NY
The LaunchPortBuilt on manufacturing operations established by Engineered Medical Systems in 1986, The LaunchPort is a Baltimore medtech venture center that helps medical-device startups move from incubation toward regulated production. Its distinctive model gives emerging companies a place to develop alongside an experienced ISO 13485 manufacturing operation, with practical support for the demanding transition from innovation to market.BALTIMORE, MD
Access for LifeFounded by Yale-trained vascular surgeon Dr. Roger Mason, Access for Life is developing a patented, sensor-equipped implantable device for vascular access during hemodialysis. The venture-backed medical-device start-up combines vascular and renal clinical expertise with engineering and business leadership, and its technology is currently undergoing in-vivo trials. Its development history includes a 2019 KidneyX Redesign Dialysis Phase 1 win and a 2022 short in-vivo trial at Mount Sinai.FLEETWOOD, NY